Imagin500 mg

Primary Indication

Imagin 500 mg is indicated for the management of Type 2 Diabetes Mellitus (T2DM) in adults.

Therapeutic Use

• Monotherapy:
  It may be used alone as a glucose-lowering agent in patients with Type 2 Diabetes Mellitus when diet and exercise alone are not sufficient to achieve glycemic control.
• Adjunct to Lifestyle Modification:
  Imeglimin is intended to be used alongside diet control and regular physical activity, forming part of a comprehensive diabetes management plan.

Clinical Purpose

Imeglimin helps improve overall glycemic control in Type 2 Diabetes Mellitus by supporting better regulation of blood glucose levels, making it suitable for patients requiring additional pharmacological support beyond lifestyle measures.

Mechanism of Action

Imagin 500 mg is a novel oral antidiabetic agent with a unique dual mechanism that improves glycemic control in Type 2 Diabetes Mellitus (T2DM) by acting on both insulin secretion and insulin sensitivity.

1. Dual Glucose-Regulating Effects

• Enhanced Glucose-Stimulated Insulin Secretion (GSIS):
  Imeglimin amplifies insulin release in response to elevated blood glucose levels and helps preserve pancreatic β-cell mass, supporting long-term insulin production capacity.
• Improved Insulin Action:
  It enhances insulin sensitivity in peripheral tissues and may reduce hepatic glucose output, contributing to better overall glucose utilization in the body.

Mitochondrial Mechanism

Imeglimin primarily acts at the cellular level by improving mitochondrial function, which is considered a key underlying defect in Type 2 Diabetes Mellitus:

• Restoration of Mitochondrial Balance:
  It modulates the mitochondrial respiratory chain by partially inhibiting Complex I and correcting impaired Complex III activity.
• Reduction of Oxidative Stress:
  By improving mitochondrial efficiency, it decreases the production of reactive oxygen species (ROS), thereby reducing oxidative damage.
• Prevention of Cell Injury:
  It helps prevent opening of the mitochondrial permeability transition pore, a process linked to cellular dysfunction and apoptosis.

Effects on Pancreatic β-Cells

• Enhances ATP production in pancreatic islets, improving insulin secretion in response to glucose.
• Stimulates the nicotinamide adenine dinucleotide (NAD⁺) salvage pathway, supporting cellular energy metabolism.
• Contributes to preservation of β-cell mass in diabetic conditions.

Metabolic Significance

Imeglimin targets a fundamental defect in Type 2 Diabetes Mellitus—impaired cellular energy metabolism—thereby improving both insulin secretion and insulin responsiveness.

Its mechanism is distinct from other antidiabetic drug classes such as:

• Biguanides
• Sulfonylureas
• GLP-1 receptor agonists

Summary

Imagin 500 mg is a first-in-class oral antidiabetic agent that improves glycemic control through dual action on insulin secretion and insulin sensitivity, primarily by restoring mitochondrial function and correcting underlying cellular energy dysfunction in Type 2 Diabetes Mellitus.

Imagin 500 mg is generally well tolerated in most patients. However, like all medications, it may cause certain side effects, which are usually mild to moderate in nature.

Common Side Effects

• Gastrointestinal Disturbances:
  The most frequently reported effects include:
  • Nausea
  • Diarrhea
  • Constipation

These symptoms are generally temporary and may improve with continued use.

Metabolic and General Effects

• Hypoglycemia (Low Blood Sugar):
  May occur, especially when used in combination with other glucose-lowering medications. Symptoms may include sweating, hunger, shakiness, and weakness.
• General Weakness or Fatigue:
  Some patients may experience a feeling of tiredness or reduced energy levels.

Clinical Considerations

• Side effects are typically mild and self-limiting.
• Risk of hypoglycemia should be monitored more closely in patients on combination therapy with insulin or sulfonylureas.

Summary

Imagin 500 mg is generally safe and well tolerated, with the most common side effects being gastrointestinal discomfort and, less commonly, symptoms related to low blood sugar.

Pregnancy

The safety of Imagin 500 mg during pregnancy has not been fully established in human studies.

• It should be used in pregnant women, or those who may become pregnant, only when clearly needed.
• Treatment should be considered only if the expected benefits outweigh the potential risks to the mother and fetus.
• Careful medical supervision is recommended throughout therapy.

Lactation (Breastfeeding)

• Breastfeeding is not recommended during treatment with Imagin 500 mg.
• Based on available animal studies, transfer of the drug into breast milk has been observed.
• To avoid potential risk to the nursing infant, breastfeeding should be discontinued during therapy.

Summary

Imagin 500 mg should be used during pregnancy only when clearly necessary, and breastfeeding should be avoided during treatment due to potential drug transfer into breast milk and lack of sufficient safety data.

Risk of Hypoglycemia

Imagin 500 mg may cause symptoms of hypoglycemia (low blood sugar), especially when used in combination with other antidiabetic agents.

• Patients should remain cautious while performing activities requiring full alertness, such as:
  • Driving vehicles
  • Operating heavy or dangerous machinery
  • Working at heights

Management of Hypoglycemia

• If symptoms of low blood sugar occur (such as sweating, dizziness, hunger, or weakness):
  • Consume sugar-containing foods or glucose immediately.
• In patients taking alpha-glucosidase inhibitors (e.g., acarbose, voglibose, miglitol) in combination therapy:
  • Glucose should be used instead of sucrose for rapid correction of hypoglycemia.

Renal Impairment Considerations

• Dose adjustment may be required in patients with renal impairment.
• Use is not recommended in severe renal dysfunction, particularly when eGFR < 15 mL/min/1.73 m².

Special Caution

• Careful monitoring of blood glucose levels is recommended during treatment, especially in patients receiving combination therapy.
• Regular assessment of renal function is advised to ensure safe use.

Summary

Imagin 500 mg should be used with caution due to the risk of hypoglycemia and in patients with impaired renal function. Dose adjustment and proper patient education are essential for safe and effective therapy.

Clinical Presentation

Specific symptoms of overdose with Imagin 500 mg have not been clearly established. However, excessive intake may potentially increase the risk of:

• Gastrointestinal discomfort
• Metabolic disturbances related to glucose control

Management of Overdose

In the event of suspected overdose, appropriate supportive medical care should be initiated promptly. Recommended measures include:

• Gastrointestinal Decontamination:
  Removal of unabsorbed drug from the gastrointestinal tract when appropriate.
• Clinical Monitoring:
  Close observation of the patient’s clinical status, including:
  • Vital signs monitoring
  • Blood glucose assessment
  • Electrocardiogram (ECG) monitoring if indicated
• Supportive Treatment:
  Symptomatic and supportive care should be provided based on the patient’s condition.

General Considerations

• There is no specific antidote for Imagin 500 mg overdose.
• Management is primarily supportive and based on clinical symptoms.

Summary

Overdose of Imagin 500 mg is managed with supportive care, gastrointestinal decontamination when appropriate, and close clinical monitoring, as no specific antidote is available.

Store below 30°C temperature and dry place, protected from light. Keep all medicines out of reach of children.